ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Cognition Therapeutics Inc

Cognition Therapeutics Inc (CGTX)

0.60615
0.00705
(1.18%)
At close: September 19 4:00PM
0.5898
-0.01635
( -2.70% )
After Hours: 4:25PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.5898
Bid
0.5899
Ask
0.6099
Volume
95,630
0.5909 Day's Range 0.6094
0.542 52 Week Range 3.44
Market Cap
Previous Close
0.5991
Open
0.6001
Last Trade
1
@
0.6099
Last Trade Time
16:22:16
Financial Volume
$ 57,295
VWAP
0.599131
Average Volume (3m)
1,057,506
Shares Outstanding
40,132,961
Dividend Yield
-
PE Ratio
-0.95
Earnings Per Share (EPS)
-0.64
Revenue
-
Net Profit
-25.79M

About Cognition Therapeutics Inc

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an o... Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Camden, Delaware, USA
Founded
-
Cognition Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGTX. The last closing price for Cognition Therapeutics was $0.60. Over the last year, Cognition Therapeutics shares have traded in a share price range of $ 0.542 to $ 3.44.

Cognition Therapeutics currently has 40,132,961 shares outstanding. The market capitalization of Cognition Therapeutics is $24.04 million. Cognition Therapeutics has a price to earnings ratio (PE ratio) of -0.95.

CGTX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0302-4.870967741940.620.620.57712009690.59718425CS
4-0.2085-26.11800075160.79830.82790.563773760.68973857CS
12-1.0902-64.89285714291.683.440.54210575061.22187338CS
26-1.2802-68.45989304811.873.440.5425615301.33379117CS
52-0.6702-53.19047619051.263.440.5423775751.44528058CS
156-11.5602-95.145679012312.1513.80.5422346112.39219672CS
260-11.5602-95.145679012312.1513.80.5422346112.39219672CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LFLYLeafly Holdings Inc
$ 3.80
(112.29%)
2.61M
AEMDAethlon Medical Inc
$ 0.6166
(53.92%)
4.85M
AENTAlliance Entertainment Holding Corporation
$ 2.6514
(25.66%)
49.27k
TNONTenon Medical Inc
$ 6.09
(21.09%)
679.22k
TCTMTCTM Kids IT Education Inc
$ 0.9997
(14.68%)
143
NCINeo Concept International Group Holdings Ltd
$ 0.66
(-21.43%)
838.86k
KOPNKopin Corporation
$ 0.81
(-15.63%)
51.15k
ARQArq Inc
$ 5.45
(-11.67%)
28.58k
MYNAMynaric AG
$ 1.15
(-10.85%)
92.92k
ANSCUAgriculture and Natural Solutions Acquisition Corporation
$ 10.45
(-9.13%)
200
AEMDAethlon Medical Inc
$ 0.6166
(53.92%)
4.85M
ALLOAllogene Therapeutics Inc
$ 2.91
(0.00%)
3.09M
SQQQProShares UltraPro Short QQQ
$ 7.78
(0.26%)
2.92M
CIBRFirst Trust ETF II First Trust NASDAQ Cybersecurity
$ 58.53
(0.03%)
2.88M
LFLYLeafly Holdings Inc
$ 3.80
(112.29%)
2.61M

CGTX Discussion

View Posts
Monksdream Monksdream 2 months ago
CGTX new 52. Week low
👍️0
Awl416 Awl416 2 months ago
T1 halt….
👍️0
Monksdream Monksdream 2 months ago
No news
https://ih.advfn.com/markets/nasdaq/premarket
👍️0
Monksdream Monksdream 2 months ago
CGTX under $3
👍️0
Monksdream Monksdream 2 months ago
Whoops, I did it, again
👍️0
Monksdream Monksdream 2 months ago
CGTX under $2
👍️0
dannyzee84 dannyzee84 4 months ago
Great stock. Future is bright. Bags packed.
👍️0
Monksdream Monksdream 5 months ago
CGTX under $2
👍️0
Monksdream Monksdream 6 months ago
CGTX under $2
👍️0
Monksdream Monksdream 7 months ago
CGTX under $2
👍️0
Monksdream Monksdream 11 months ago
CGTX new 52 week low
👍️0
Monksdream Monksdream 12 months ago
CGTX under $2
👍️0
artfulife artfulife 1 year ago
Is that a wild guess or is there some reasoning behind your statement?
👍️0
willlbone willlbone 1 year ago
Time to buy.
👍️0
crudeoil24 crudeoil24 2 years ago
Great! I believe we'll do quite well on share price surge!
👍️ 1
tw0122 tw0122 2 years ago
Already been here for a few weeks …lol. One of my very few longer term hold OTC plays.
Thanks..
👍️0
crudeoil24 crudeoil24 2 years ago
Nice "pop" on FDA phase II news! If you have time, you may want to check out GDVM. Symbol change happening any day. Two hours of reading you'll be buying shares.
👍️0
tw0122 tw0122 2 years ago

The START study is supported by a grant of approximately $81 million for 5 years from the National Institutes of Health’s (NIH) National Institute on Aging (NIA) to accelerate development of new therapies for Alzheimer’s disease.

“The START study and ACTC represent some of the many ways that NIA funds research into novel therapeutics for treating Alzheimer's and related dementias,” stated Laurie Ryan, Ph.D., an NIA clinical research program official.

“We appreciate the continued support of the NIA, which has been an important partner in our work to develop CT1812. Our lead drug candidate is a potentially disease-modifying oral therapeutic for the treatment of Alzheimer's disease and other neurodegenerative conditions,” added Cognition president and CEO, Lisa Ricciardi. “With the NIA's funding, we have been able to complete a series of preclinical and clinical trials, thus advancing our understanding of CT1812 and the role of the sigma-2 (s-2) receptor in Alzheimer’s disease. We look forward to recruiting patients for the START study with our collaboration partners at the ACTC.”

“ACTC aims to accelerate Alzheimer’s drug development, working with academic and industry partners,” said Paul Aisen, M.D., professor of neurology at the University of Southern California and director of the Alzheimer's Therapeutic Research Institute. “The START study is an important component of ACTC efforts. Having an authorized protocol for the START study is a critical step in preparing to open clinical sites for the trial by mid-2023.”

NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or early Alzheimer’s disease. This randomized placebo-controlled trial will be conducted at approximately 50-to-60 sites in North America including those premier institutions in the Alzheimer's Clinical Trials Consortium (ACTC). CT1812 is an investigational oral small molecule that binds to a receptor on synapses and is designed to prevent the toxic effects of soluble beta amyloid (Aß) oligomers on neurons, which drive the progression of neurodegenerative diseases such as Alzheimer’s disease.


“The initial clinical results observed with CT1812 are encouraging and we look forward to advancing it into the START trial to evaluate its effects in a larger study in people with early Alzheimer’s disease,” said Christopher H. van Dyck, M.D., director of the Yale Alzheimer's Disease Research Center and primary investigator of the START study. “We envision a future with multiple treatment options, to be used alone or in combination according to evidence, to achieve the greatest slowing of Alzheimer's disease progression.”
👍️0
anderson800 anderson800 2 years ago
Chart is looking better all of the time. The 50 day MA is only about 15 cents away from the 200 day and when we get the golden cross that should trigger a lot of buy signals.
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 2 years ago
$CGTX Love the chart..looking for continuation next week..

https://stockcharts.com/c-sc/sc?s=CGTX&p=D&b=5&g=0&i=0&r=1669471320227
👍️ 1
anderson800 anderson800 2 years ago
Hopefully this has seen its low and now is starting a new uptrend. I just grabbed my first 1000 shares today after seeing the CEO added 71,000 shares.
👍️0
turning stone turning stone 2 years ago
Nope but not any major loss.
👍️0
Pedro2004 Pedro2004 2 years ago
Were you able to get-out with a profit today?
👍️0
turning stone turning stone 2 years ago
While the stock is dropping on no relative news it is a good time to think about purchasing more shares. I have been averaging down and would not mind $2.00/share to bring me more in line with what makes me comfortable.
👍️0
turning stone turning stone 2 years ago
As a new investor in CGTX I look forward to new and interesting posts on the board. I am tired of plain B-S from those who get off on seeing there jibber in print.
👍️0
turning stone turning stone 2 years ago
Hope there is very little shorting done to this stock!!!!!
👍️0
turning stone turning stone 2 years ago
Hopefully we have a winner by end of this year.
👍️0
turning stone turning stone 2 years ago
I hope in the Mid 3's is a good starting point
👍️0
turning stone turning stone 2 years ago
As a new shareholder I fit the need going to be 77.
👍️0
crudeoil24 crudeoil24 2 years ago
In a report released today, Mayank Mamtani from B.Riley Financial maintained a Buy rating on Cognition Therapeutics (CGTX – Research Report), with a price target of $15.00. The company's shares closed last Thursday at $2.75, close to its 52-week low of $2.31. According to TipRanks.com, Mamtani is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -22.4% and a 27.8% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Spectrum Pharmaceuticals, and Madrigal Pharmaceuticals. Cognition Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
https://www.tipranks.com/news/blurbs/b-riley-financial-thinks-cognition-therapeutics-stock-is-going-to-recover-5?utm_source=advfn.com&utm_medium=referral
👍️0
FooBarAndGrill FooBarAndGrill 3 years ago
Welcome to Cognition Therapeutics Inc (CGTX).
👍️0

Your Recent History

Delayed Upgrade Clock